FINWIRES · TerminalLIVE
FINWIRES

Recce Pharmaceuticals Gets Ethics Approval for New Study Arm in Phase 3 Trial of Diabetic Foot Infection Treatment

By

Recce Pharmaceuticals (ASX:RCE) gained Human Research Ethics Committee approval for an amendment to its phase 3 clinical trial of Recce 327 topical gel for the potential treatment of diabetic foot infections in Australia, according to a Wednesday filing with the Australian bourse.

The amendment adds a new randomized, active-controlled, non-inferiority study arm enrolling 208 participants, which will allow the company to generate comparative clinical data for the gel against antibiotic treatment options.

The updated protocol also introduces wound imaging, which adds a further layer of objective assessment of the infection to strengthen the Recce 327 data package for global regulatory submissions, the company said.

Related Articles

Asia

Wasco Greenergy Appoints Group MD as CEO Opts for Early Retirement

Wasco Greenergy (KLSE:GENERGY) said its chief executive officer, Lee Yee Chong, opted for early retirement from the role, effective Dec. 31, according to a Monday filing with Bursa Malaysia.Shares slid over 2% in Tuesday's late morning trade.Lee joined the group in 1995 and has held several key leadership positions within Wasco over the years.The company appointed Wong Yin Kee as group managing director, effective Aug. 17, to facilitate the transition of authority and responsibilities.

KLSE:GENERGY
Asia

Yuntianhua's H1 Profit Rises 6%, Revenue Drops 9%; Shares Up 3%

Yunnan Yuntianhua's (SHA:600096) net profit attributable to shareholders for the first half rose 6.1% to 2.93 billion yuan from 2.76 billion yuan a year earlier, according to a Tuesday disclosure on the Shanghai bourse.Earnings per share increased year on year to 1.61 yuan from 1.52 yuan.Operating revenue fell 8.9% to 22.8 billion yuan from 25.1 billion yuan in the previous year.The board of directors proposed a cash dividend of 2 yuan for every 10 shares.The high-quality diammonium phosphate supplier's shares rose nearly 3% during the morning trade.

SHA:600096
Asia

Market Chatter: CJ Group Sets KRW12 Trillion Revenue Target for North America by 2028

CJ Group expects its total revenue from North America to expand to 12 trillion won by 2028, driven by rising demand for Korean food, entertainment, and beauty products, The Korean Times reported Monday.The South Korean group, led by holding company CJ (KRX:001040), unveiled its target following a strategy meeting with the group chairman in Los Angeles last week.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

KRX:001040